Reaction to FDA’s approval of drug for Alzheimer’s

Big news in the fight against Alzheimer’s. The FDA has given full approval to Leqembi, which has shown it can slow the progression of the disease for some patients in the early stages.

There are still some hoops to get through, but advocates say this is real progress.

Christine Nelson, the Alzheimer’s Association Ambassador for Minnesota’s 8th Congressional District, said, “It’s rewarding to see things change and move forward. This motivates me.”

She’s been focused on this since her mother died from the disease. And now another family member has been diagnosed.

Susan Parriott, the CEO of the Minnesota-North Dakota chapter of the Alzheimer’s Association, added, “When you have success in research, it really is easy to start building upon that. More scientists get interested in the research game.”

She also said, “I think it gives people recently diagnosed some real hope that their future can be changed, and they don’t have to have the normal path with Alzheimer’s. I also hope it encourages people to get diagnosed.”